A Phase 3 interventional study of Pomalidomide 0.5 mg and Placebo in Primary Myelofibrosis and MPN-associated Myelofibrosis, sponsored by Celgene. Completed at 87 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-17.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb — 1 open to participants now, 3 under way, 1 of them phase 3. Primary Myelofibrosis · Bristol-Myers Squibb.
Among the 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2010, is one of 4 in phase 3, and was the 3rd registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.
Browse Primary Myelofibrosis studies →1 of the 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb is open now, in 1 country. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 4
First in 2007; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 267 is above the median of 43 across 490 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 92 across the 10 interventional studies, 150 across the 3 observational. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to determine whether pomalidomide is safe and effective in reversing red blood cell (RBC)-transfusion-dependence in persons with myeloproliferative neoplasm (MPN)-associated myelofibrosis (global study) and in reversing anemia in Chinese with MPN-associated myelofibrosis and severe anemia not receiving RBC-transfusions (China extension study only)
The multicenter global study was conducted in 15 countries including Australia, Austria, Belgium, Canada, China, France, Germany, Italy, Japan, the Netherlands, Russia, Spain, Sweden, the United Kingdom, and the United States. The global study enrolled participants with myeloproliferative neoplasm (MPN)-associated myelofibrosis and RBC-transfusion-dependence. Participants were randomly assigned to receive pomalidomide or placebo in a blinded fashion.
In most countries participating in the global study, RBC-transfusions are typically given for a hemoglobin level \<80-90 g/L. In China, RBC-transfusions are rarely given unless the hemoglobin level is \<60 g/L. Consequently, few Chinese with MPN-associated myelofibrosis meet RBC-transfusion-dependence criteria of the global study. A China-specific extension was developed to test the ability of pomalidomide to improve severe anemia (defined as a hemoglobin \< 80 g/L for ≥ 84 days in persons not receiving RBC-transfusions).
The China-specific extension study consisted of a single-arm, open-label study in adults with MPN-associated myelofibrosis and severe anemia not receiving RBC transfusions with the objective of describing the frequency of anemia response.
The Global (intent-to-treat [ITT] and safety) population in the main study and the China extension (ITT and safety) population are mutually exclusive.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
RBC-transfusion-dependence (global study):
determining eligibility.
RBC-transfusions due to chemotherapy-induced anemia are not scored in determining eligibility.
No RBC-transfusion within 6 months prior to enrollment.
Exclusion Criteria:
Prior history of ,other than the disease being studied, unless the subject has been free of the malignancy for ≥ 5 years with the following exceptions:
Any of the following laboratory abnormalities:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received pomalidomide 0.5 mg/day by mouth for at least 168 days unless there were unacceptable side effects or disease progression. Participants who were RBC-transfusion independent or experienced clinical benefit (defined as a reduction from Baseline of ≥ 50% in RBC-transfusion frequency during the prior 84-day interval) could continue to receive pomalidomide until loss of RBC-transfusion independence response or clinical benefit, or other criteria for treatment discontinuation applied.
Drug: Pomalidomide 0.5 mg
Participants received placebo taken by mouth once daily for at least 168 days unless there were unacceptable side effects or disease progression. Participants who were RBC-transfusion independent or experienced clinical benefit could continue to receive placebo until loss of RBC- transfusion independence response or clinical benefit, or other criteria for treatment discontinuation applied.
Drug: Placebo
Participants received pomalidomide 0.5 mg/day by mouth for at least 168 days unless there were unacceptable side effects, disease progression, or they received a RBC-transfusion. Participants who experienced anemia response could continue treatment until the response was lost or other criteria for treatment discontinuation applied.
Drug: Pomalidomide
Pomalidomide 0.5 mg capsule taken by mouth once daily. Immunomodulatory agent with demonstrated efficacy in the treatment of subjects with RBC-transfusion-dependence associated with MNP-associated myelofibrosis.
Also known as: CC-4047; Pomalyst; Imnovid
Placebo Comparator to active drug; Placebo capsule taken by mouth once daily
Pomalidomide 0.5 mg capsule taken by mouth once daily.
Also known as: CC-4047, Pomalyst, Imnovid
Percentage of Participants Who Achieved RBC-Transfusion Independence
RBC-transfusion independence was defined as the absence of RBC transfusions for any consecutive 84-day interval.
Time frame: 168 days
China Extension: Number of Participants Achieving a Hemoglobin Increase of ≥ 15 g/L Compared to Baseline for ≥ 84 Consecutive Days
A response in the China extension study was defined as an increase in hemoglobin ≥ 15 g/L above baseline value (in the absence of RBC transfusion) for ≥ 84 consecutive days.
Time frame: From the first dose of study drug until treatment discontinuation; median treatment duration was 24.0 weeks.
Overall Survival
The time from randomization to the death or to the latest date when participants are known to be alive. Overall survival was analyzed using Kaplan-Meier method; participants who were alive or lost to follow-up were censored at the latest date they were known to be alive.
Time frame: From first dose of study drug up to end of study; median follow-up time was 19.1 months in the pomalidomide 0.5 mg arm and 17.6 months in the placebo arm.
Duration of RBC-Transfusion Independence
The duration of RBC-transfusion independence is the time from the date at which the first RBC-transfusion independence started to the date of another RBC-transfusion given at least 84 days after the time the transfusion independence started. The duration of the RBC-transfusion independence was analyzed using the Kaplan-Meier method. Data were censored at the end of the treatment phase for participants who had not received another RBC-transfusion after the start of transfusion independence by the end of treatment phase.
Time frame: From first dose of study drug up to 28 days after last dose, as of the data cut-off date of 16 Jan 2013; median treatment duration was 23.6 weeks in the pomalidomide arm and 23.9 weeks in the placebo arm.
Time to RBC-Transfusion Independence
Time to response was measured from first dose of study drug to the start of the first response. The start date of the response was defined as one day after the last date of an RBC-transfusion for participants who received a RBC-transfusion after the first dose, and as the date of the first dose of study drug for participants who received no RBC-transfusions during the 84 days after the first dose of study drug.
Time frame: 168 days
Number of Participants With Treatment-emergent Adverse Events (TEAE)
A TEAE is an adverse event (AE) that starts on or after the first dose of study drug. The severity of each AE was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE),Version 4.0 and according to the following scale: Grade 1 = Mild (transient or mild discomfort; no limitation in activity; no medical intervention/therapy required); Grade 2 = Moderate (mild to moderate limitation in activity, some assistance may be needed; minimal medical intervention/therapy required); Grade 3 = Severe (marked limitation in activity, assistance usually required; medical intervention/therapy required, hospitalization possible); Grade 4 = Life-threatening (extreme limitation in activity, significant assistance or medical intervention/therapy required, hospitalization or hospice care probable); Grade 5 = Death Drug-related (related) AEs are those suspected by the Investigator as being related to administration of study drug
Time frame: From the first dose of study drug until 28 days after last dose; median treatment duration was 23.7 weeks in the pomalidomide arm, 23.9 weeks in the placebo arm, and 24.0 weeks in the China extension pomalidomide arm.
Healthcare Resource Utilization
Time frame: From first dose of study drug up to 28 days after last dose, as of the data cut-off date of 16 Jan 2013; median treatment duration was 23.6 weeks in the pomalidomide arm and 23.9 weeks in the placebo arm.
Change From Baseline in EuroQoL-5D (EQ-5D) Health Index Score
EQ-5D is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D includes 2 components: the EQ-5D health state profile (descriptive system) and the EQ-5D visual analog scale (VAS). For the health state profile participants rate their perceived health state today on 5 dimensions: mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression on a Likert-type scale from 1 to 3, where 1 = "no problems," 2 = "some problems," and 3 = "extreme problems." The EQ-5D Health Utility Index (HUI) was generated from the five health state domain scores, and ranges from -0.594 (worst) and 1 (best) imaginable health state, with -0.594 representing an "unconscious" health state.
Time frame: Baseline and Days 85 and 169
Change From Baseline in EuroQoL-5D (EQ-5D) Visual Analog Scale
EQ-5D is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D includes 2 components: the EQ-5D health state profile (descriptive system) and the EQ-5D visual analog scale (VAS). On the VAS the participant rates his/her health state on a line from 0 (worst imaginable health) to 100 (best imaginable health).
Time frame: Baseline and Days 85 and 169
Change From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Total Score
The FACT-An is a 47-item, cancer-specific questionnaire consisting of a core 27-item general questionnaire measuring the four general domains of QoL (physical, social/family, emotional and functional well-being), and an additional 20-item anemia questionnaire (FACT-An Anemia subscale) that measures 13 fatigue-associated items (FACT-F Fatigue subscale) and seven non-fatigue-related items. Each item is scored using a 5-point Likert rating scale (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very much). FACT-An total score is calculated by adding all the FACT-An subscales together. The total score ranges from 0-188 with higher scores representing better QOL.
Time frame: Baseline and Days 85 and 169
Participants in the global study were enrolled at 72 clinical centers in 15 countries. In addition, the China-specific extension study enrolled participants with myeloproliferative neoplasm (MPN)-associated myelofibrosis and severe anemia not receiving red blood cell (RBC)-transfusions at 5 sites in China.
| Milestone | Pomalidomide 0.5 mg | Placebo | China Extension: Pomalidomide 0.5 mg |
|---|---|---|---|
| Started | 168 | 84 | 15 |
| Received study drug | 167 | 83 | 15 |
| Completed | 168 | 84 | 15 |
| Not completed | 0 | 0 | 0 |
RBC-transfusion independence was defined as the absence of RBC transfusions for any consecutive 84-day interval.
| percentage of participants | Pomalidomide 0.5 mg | Placebo |
|---|---|---|
| Percentage of Participants Who Achieved RBC-Transfusion Independence | 17.3 (11.88 to 23.84) | 16.7 (9.42 to 26.38) |
A response in the China extension study was defined as an increase in hemoglobin ≥ 15 g/L above baseline value (in the absence of RBC transfusion) for ≥ 84 consecutive days.
| Participants | China Extension: Pomalidomide 0.5 mg |
|---|---|
| China Extension: Number of Participants Achieving a Hemoglobin Increase of ≥ 15 g/L Compared to Baseline for ≥ 84 Consecutive Days | 1 |
The time from randomization to the death or to the latest date when participants are known to be alive. Overall survival was analyzed using Kaplan-Meier method; participants who were alive or lost to follow-up were censored at the latest date they were known to be alive.
| months | Pomalidomide 0.5 mg | Placebo |
|---|---|---|
| Overall Survival | 24.2 (19.5 to 33.5) | 26.2 (18.0 to 32.6) |
The duration of RBC-transfusion independence is the time from the date at which the first RBC-transfusion independence started to the date of another RBC-transfusion given at least 84 days after the time the transfusion independence started. The duration of the RBC-transfusion independence was analyzed using the Kaplan-Meier method. Data were censored at the end of the treatment phase for participants who had not received another RBC-transfusion after the start of transfusion independence by the end of treatment phase.
| months | Pomalidomide 0.5 mg | Placebo |
|---|---|---|
| Duration of RBC-Transfusion Independence | NA (4.8 to NA) | 5.8 (3.0 to NA) |
Time to response was measured from first dose of study drug to the start of the first response. The start date of the response was defined as one day after the last date of an RBC-transfusion for participants who received a RBC-transfusion after the first dose, and as the date of the first dose of study drug for participants who received no RBC-transfusions during the 84 days after the first dose of study drug.
| weeks | Pomalidomide 0.5 mg | Placebo |
|---|---|---|
| Time to RBC-Transfusion Independence | 6.9 (0.1 to 20.1) | 2.4 (0.1 to 15.4) |
A TEAE is an adverse event (AE) that starts on or after the first dose of study drug. The severity of each AE was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE),Version 4.0 and according to the following scale: Grade 1 = Mild (transient or mild discomfort; no limitation in activity; no medical intervention/therapy required); Grade 2 = Moderate (mild to moderate limitation in activity, some assistance may be needed; minimal medical intervention/therapy required); Grade 3 = Severe (marked limitation in activity, assistance usually required; medical intervention/therapy required, hospitalization possible); Grade 4 = Life-threatening (extreme limitation in activity, significant assistance or medical intervention/therapy required, hospitalization or hospice care probable); Grade 5 = Death Drug-related (related) AEs are those suspected by the Investigator as being related to administration of study drug
| Participants | Pomalidomide 0.5 mg | Placebo | China Extension: Pomalidomide 0.5 mg |
|---|---|---|---|
| Any adverse event (AE) | 164 | 81 | 12 |
| Adverse event suspected as related to study drug | 90 | 32 | 3 |
| Adverse event leading to dose interruption | 48 | 17 | 2 |
| Drug-related AE leading to dose interruption | 26 | 6 | 1 |
| AE leading to discontinuation of study drug | 53 | 14 | 0 |
| Related AE leading to study drug discontinuation | 21 | 8 | 0 |
| Grade 3/4 adverse event | 100 | 44 | 4 |
| Grade 3/4 AE related to study drug | 45 | 13 | 0 |
| Grade 3/4 AE leading to study drug discontinuation | 33 | 9 | 0 |
| Grade 3/4 AE leading to dose interruption | 36 | 14 | 1 |
| Grade 5 adverse event | 17 | 10 | 0 |
| Grade 5 AE related to study drug | 1 | 3 | 0 |
| Serious adverse event (SAE) | 76 | 29 | 0 |
| SAE related to study drug | 24 | 7 | 0 |
| SAE leading to discontinuation of study drug | 31 | 8 | 0 |
| SAE leading to dose interruption | 22 | 7 | 0 |
No measurements were reported for this outcome.
EQ-5D is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D includes 2 components: the EQ-5D health state profile (descriptive system) and the EQ-5D visual analog scale (VAS). For the health state profile participants rate their perceived health state today on 5 dimensions: mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression on a Likert-type scale from 1 to 3, where 1 = "no problems," 2 = "some problems," and 3 = "extreme problems." The EQ-5D Health Utility Index (HUI) was generated from the five health state domain scores, and ranges from -0.594 (worst) and 1 (best) imaginable health state, with -0.594 representing an "unconscious" health state.
| score on a scale | Pomalidomide 0.5 mg | Placebo |
|---|---|---|
| Day 85 | -0.0385 ± 0.2480 | -0.0298 ± 0.2129 |
| Day 169 | -0.0202 ± 0.1666 | 0.0766 ± 0.1546 |
EQ-5D is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D includes 2 components: the EQ-5D health state profile (descriptive system) and the EQ-5D visual analog scale (VAS). On the VAS the participant rates his/her health state on a line from 0 (worst imaginable health) to 100 (best imaginable health).
| units on a scale | Pomalidomide 0.5 mg | Placebo |
|---|---|---|
| Day 85 | 2.0 ± 20.78 | -1.4 ± 14.07 |
| Day 169 | 2.9 ± 22.85 | 0.3 ± 24.25 |
The FACT-An is a 47-item, cancer-specific questionnaire consisting of a core 27-item general questionnaire measuring the four general domains of QoL (physical, social/family, emotional and functional well-being), and an additional 20-item anemia questionnaire (FACT-An Anemia subscale) that measures 13 fatigue-associated items (FACT-F Fatigue subscale) and seven non-fatigue-related items. Each item is scored using a 5-point Likert rating scale (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very much). FACT-An total score is calculated by adding all the FACT-An subscales together. The total score ranges from 0-188 with higher scores representing better QOL.
| units on a scale | Pomalidomide 0.5 mg | Placebo |
|---|---|---|
| Day 85 | -2.1 ± 20.32 | 4.3 ± 18.73 |
| Day 169 | 6.2 ± 20.49 | 11.9 ± 18.60 |
Collected over All-cause mortality data are reported from first dose of study drug up to end of study; maximum follow-up time was 85 months. Adverse events are reported from the first dose of study drug until 28 days after last dose; median treatment duration was 23.7 weeks in the pomalidomide arm, 23.9 weeks in the placebo arm, and 24.0 weeks in the China extension pomalidomide arm.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Global Study: Pomalidomide 0.5 mg | 115/167 (68.9%) | 76/167 (45.5%) | 155/167 (92.8%) |
| Global Study: Placebo | 54/83 (65.1%) | 29/83 (34.9%) | 76/83 (91.6%) |
| China Extension: Pomalidomide 0.5 mg | 8/15 (53.3%) | 0/15 (0%) | 12/15 (80%) |
| Event | Global Study: Pomalidomide 0.5 mg | Global Study: Placebo | China Extension: Pomalidomide 0.5 mg |
|---|---|---|---|
| ANAEMIABlood and lymphatic system disorders | 10/167 | 3/83 | 0/15 |
| MYELOFIBROSISNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 9/167 | 3/83 | 0/15 |
| PNEUMONIAInfections and infestations | 6/167 | 4/83 | 0/15 |
| PYREXIAGeneral disorders | 5/167 | 3/83 | 0/15 |
| CARDIAC FAILURECardiac disorders | 5/167 | 1/83 | 0/15 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 3/167 | 2/83 | 0/15 |
| DIARRHOEAGastrointestinal disorders | 0/167 | 2/83 | 0/15 |
| MULTI-ORGAN FAILUREGeneral disorders | 2/167 | 2/83 | 0/15 |
| OEDEMA PERIPHERALGeneral disorders | 4/167 | 0/83 | 0/15 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 3/167 | 1/83 | 0/15 |
| Event | Global Study: Pomalidomide 0.5 mg | Global Study: Placebo | China Extension: Pomalidomide 0.5 mg |
|---|---|---|---|
| OEDEMA PERIPHERALGeneral disorders | 53/167 | 14/83 | 1/15 |
| DIARRHOEAGastrointestinal disorders | 35/167 | 17/83 | 2/15 |
| FATIGUEGeneral disorders | 35/167 | 17/83 | 3/15 |
| NAUSEAGastrointestinal disorders | 21/167 | 16/83 | 0/15 |
| PYREXIAGeneral disorders | 30/167 | 9/83 | 2/15 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 28/167 | 8/83 | 1/15 |
| NEUTROPENIABlood and lymphatic system disorders | 25/167 | 4/83 | 0/15 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 21/167 | 12/83 | 1/15 |
| DIZZINESSNervous system disorders | 17/167 | 12/83 | 0/15 |
| CONSTIPATIONGastrointestinal disorders | 24/167 | 9/83 | 0/15 |
Intent to Treat (ITT) population included all randomized (global study) or enrolled (China extension study) participants
| Age, Continuous(years) | Pomalidomide 0.5 mg | Placebo | China Extension: Pomalidomide 0.5 mg | Total |
|---|---|---|---|---|
| Global study | 69.0 (40.0 to 90.0) | 69.0 (44.0 to 81.0) | — | 69.0 (40.0 to 90.0) |
| China extension study | — | — | 63.0 (41.0 to 76.0) | 63.0 (41.0 to 76.0) |
| Sex: Female, Male(Participants) | Pomalidomide 0.5 mg | Placebo | China Extension: Pomalidomide 0.5 mg | Total |
|---|---|---|---|---|
| Female | 41 | 28 | 6 | 75 |
| Male | 127 | 56 | 9 | 192 |
| Ethnicity (NIH/OMB)(Participants) | Pomalidomide 0.5 mg | Placebo | China Extension: Pomalidomide 0.5 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 0 | 4 |
| Not Hispanic or Latino | 144 | 79 | 15 | 238 |
| Unknown or Not Reported | 21 | 4 | 0 | 25 |
| Race/Ethnicity, Customized(Participants) | Pomalidomide 0.5 mg | Placebo | China Extension: Pomalidomide 0.5 mg | Total |
|---|---|---|---|---|
| American Indian or Alaskan Native | 1 | 0 | 0 | 1 |
| Asian | 20 | 11 | 15 | 46 |
| Black or African American | 2 | 3 | 0 | 5 |
| Native Hawaiian or Other Pacific Islanders | 1 | 0 | 0 | 1 |
| White | 122 | 66 | 0 | 188 |
| Other | 3 | 0 | 0 | 3 |
| Missing | 19 | 4 | 0 | 23 |
| Baseline RBC Transfusion Burden(units per 28 days) | Pomalidomide 0.5 mg | Placebo | China Extension: Pomalidomide 0.5 mg | Total |
|---|---|---|---|---|
| Global study | 2.7 (1.3 to 13.3) | 2.8 (1.3 to 10.0) | — | 2.7 (1.3 to 13.3) |
| China extension study | — | — | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Pomalidomide 0.5 mg | Placebo | China Extension: Pomalidomide 0.5 mg | Total |
|---|---|---|---|---|
| 0 (Fully active) | 53 | 22 | 5 | 80 |
| 1 (Restricted but ambulatory) | 85 | 47 | 9 | 141 |
| 2 (Ambulatory but unable to work) | 30 | 15 | 1 | 46 |
| 3 (Limited self-care) | 0 | 0 | 0 | 0 |
| 4 (Completely disabled) | 0 | 0 | 0 | 0 |
| Disease Sub-type(Participants) | Pomalidomide 0.5 mg | Placebo | China Extension: Pomalidomide 0.5 mg | Total |
|---|---|---|---|---|
| Primary myelofibrosis | 127 | 65 | 10 | 202 |
| Post-polycythemia vera myelofibrosis | 17 | 8 | 2 | 27 |
| Post-essential thrombocythemia myelofibrosis | 23 | 11 | 3 | 37 |
| Missing | 1 | 0 | 0 | 1 |
Ran from Sep 2010 to primary completion in Jan 2013, 27 months.
Results were first posted in Mar 2014, 1 year 2 months after primary completion.
Of 22 phase 3 interventional studies under Primary Myelofibrosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 68. This study's 27 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pomalidomide